Rhenman & Partners Asset Management Ab Aerie Pharmaceuticals Inc Transaction History

Rhenman & Partners Asset Management Ab

$1.2 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$4.95 - $9.16 $132,907 - $245,946	-26,850 Reduced 4.56%	562,350 $4.22 Million
Q1 2022 May 13, 2022	SELL	$5.64 - $9.8 $906,912 - $1.58 Million	-160,800 Reduced 21.44%	589,200 $5.36 Million
Q1 2021 May 14, 2021	SELL	$13.12 - $20.9 $1.31 Million - $2.09 Million	-100,000 Reduced 11.76%	750,000 $13.4 Million
Q3 2020 Oct 13, 2020	BUY	$10.46 - $14.46 $2.72 Million - $3.76 Million	260,000 Added 44.07%	850,000 $10 Million
Q2 2020 Jul 16, 2020	SELL	$12.0 - $16.13 $1.56 Million - $2.1 Million	-130,000 Reduced 18.06%	590,000 $8.71 Million
Q1 2020 Apr 16, 2020	BUY	$11.84 - $25.52 $236,800 - $510,400	20,000 Added 2.86%	720,000 $9.72 Million
Q4 2019 Jan 17, 2020	BUY	$17.72 - $25.1 $3.99 Million - $5.65 Million	225,000 Added 47.37%	700,000 $16.9 Million
Q3 2019 Oct 16, 2019	BUY	$18.41 - $28.0 $3.96 Million - $6.02 Million	215,000 Added 82.69%	475,000 $9.13 Million
Q1 2019 Apr 11, 2019	SELL	$36.32 - $49.25 $726,400 - $985,000	-20,000 Reduced 7.14%	260,000 $12.4 Million
Q4 2018 Feb 05, 2019	BUY	$33.0 - $60.04 $3.3 Million - $6 Million	100,000 Added 55.56%	280,000 $10.1 Million
Q3 2018 Oct 03, 2018	BUY	$56.15 - $73.9 $6.18 Million - $8.13 Million	110,000 Added 157.14%	180,000 $11.1 Million
Q2 2018 Jul 20, 2018	BUY	$47.85 - $70.45 $1.44 Million - $2.11 Million	30,000 Added 75.0%	70,000 $4.73 Million
Q1 2018 Apr 11, 2018	SELL	$51.15 - $61.0 $4.44 Million - $5.3 Million	-86,829 Reduced 68.46%	40,000 $2.17 Million
Q4 2017 Jan 19, 2018	BUY	$50.85 - $65.1 $299,862 - $383,894	5,897 Added 4.88%	126,829 $7.58 Million
Q3 2017 Oct 13, 2017	BUY	$48.6 - $60.1 $5.88 Million - $7.27 Million	120,932	120,932 $5.88 Million

Others Institutions Holding AERI

# of Institutions

Shares Held

2.4M

Call Options Held

Put Options Held

View Full List

About AERIE PHARMACEUTICALS INC

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

More about AERI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account